Transgene Biotek

Transgene Biotek Current Assets

The Current Assets of Transgene Biotek (526139.BO) as of Oct 30, 2026 is 9.58 M INR. In the previous year, Current Assets was 9.80 M INR — a change of -2.26% (lower).

Current Assets

9.58 MINR

YoY

-2.26%

Last updated:

Current Assets of Transgene Biotek is 2026 9.58 M INR. Current Assets of Transgene Biotek was 2025 9.80 M INR. It decreases by -2.26% lower compared to the previous year.

The Transgene Biotek Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2019
5.50 M INR
Jan 1, 2020
6.43 M INR
Jan 1, 2021
6.29 M INR
Jan 1, 2022
6.83 M INR
Jan 1, 2023
8.91 M INR
Jan 1, 2024
424,000.00 INR
Jan 1, 2025
9.80 M INR
Jan 1, 2026
9.58 M INR
The Transgene Biotek Current Assets history
YEARCurrent AssetsYoY
9.58 MINR-2.26%
9.80 MINR+2,210.85%
424,000.00INR-95.24%
8.91 MINR+30.39%
6.83 MINR+8.69%
6.29 MINR-2.19%
6.43 MINR+16.83%
5.50 MINR-20.41%
6.91 MINR-4.69%
7.25 MINR-79.02%
34.58 MINR-81.07%
182.61 MINR-9.69%
202.20 MINR-2.55%
207.50 MINR-33.41%
311.60 MINR+170.96%
115.00 MINR+618.75%
16.00 MINR-67.35%
49.00 MINR+5.83%
46.30 MINR+175.60%
16.80 MINR+30.23%
12.90 MINR+27.72%
10.10 MINR-58.26%
24.20 MINR+37.50%
17.60 MINR+53.04%
11.50 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Transgene Biotek Stock analysis

What does Transgene Biotek do? Transgene Biotek Ltd. generates revenue through the sale of diagnostic kits and its portfolio of products, including oncology, auto-immunity, drug delivery, and biogenerics solutions. The company offers TrabiAAV, a platform for delivering miRNAs, ShRNAs, and immunogens in gene therapy, and TrabiORAL, which enables oral delivery of proteins and peptides for treating human diseases. Its TBL-1203 product strengthens cell-mediated immunity to eliminate HIV without retroviral therapy, while Tacrolimus suppresses the immune system to prevent organ transplant rejection. These products are targeted at healthcare providers, research institutions, and pharmaceutical companies seeking advanced therapeutic solutions. The firm’s R&D focus on vaccines, oncology, and new drug delivery technologies supports its product development pipeline. TrabiAAV and TrabiORAL are positioned as innovative delivery platforms, while TBL-1203 and Tacrolimus address specific medical needs in HIV treatment and transplant medicine. The company’s diagnostic kits cater to clinical laboratories and hospitals requiring reliable testing solutions for oncology and autoimmune conditions. Transgene Biotek Ltd. serves healthcare professionals, pharmaceutical firms, and research organizations through its specialized products. Its oncology and auto-immunity kits are used in diagnostic settings, while its therapeutic platforms like TrabiAAV and TrabiORAL support drug development for complex diseases. The company’s focus on biogenerics and novel delivery systems aligns with market demands for cost-effective and targeted therapies. Transgene Biotek is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene Biotek stock

Current Assets of Transgene Biotek is 9.58 M INR in 2026.

Current Assets of Transgene Biotek changed from 9.80 M INR to 9.58 M INR, representing a -2.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Transgene Biotek since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Transgene Biotek historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Transgene Biotek

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Transgene Biotek